NAM
CSTL icon

Nexpoint Asset Management’s Castle Biosciences CSTL Stock Holding History

Nexpoint Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-707,032
Closed -$36.4M – 152
2020
Q3 		$36.4M Hold
707,032
– – 8.23% 2
2020
Q2 		$26.6M Hold
707,032
– – 6.01% 4
2020
Q1 		$21.1M Hold
707,032
– – 3.98% 6
2019
Q4 		$24.3M Sell
707,032
-323,963
-31% -$7.92M 1.84% 12
2019
Q3 		$18.6M Buy
+1,030,995
New +$22.9M 1.16% 15

Other funds holding CSTL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nexpoint Asset Management's CSTL Position: Q4 2020 in Review

Nexpoint Asset Management sold out of Castle Biosciences (CSTL) in Q4 2020, closing a stake of 707,032 shares — an estimated $36.4M sold.

Nexpoint Asset Management first reported a position in CSTL in Q3 2019 and held it in 5 quarters. The position peaked at $36.4M in Q3 2020. 163 funds tracked by Wall St. Rank hold CSTL as of Q4 2020.

  • Nexpoint Asset Management reported no remaining Castle Biosciences position as of Q4 2020 after selling out during the quarter.
  • Nexpoint Asset Management sold 707,032 Castle Biosciences shares in Q4 2020, an estimated $36.4M.
  • Nexpoint Asset Management first reported a position in Castle Biosciences in Q3 2019 and held it in 5 quarters.
  • Nexpoint Asset Management's Castle Biosciences position peaked at $36.4M in Q3 2020.
  • 163 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2020.

Based on Nexpoint Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.